JP4623719B2 - 血管形成依存性症状を治療または予防する方法 - Google Patents
血管形成依存性症状を治療または予防する方法 Download PDFInfo
- Publication number
- JP4623719B2 JP4623719B2 JP2004556884A JP2004556884A JP4623719B2 JP 4623719 B2 JP4623719 B2 JP 4623719B2 JP 2004556884 A JP2004556884 A JP 2004556884A JP 2004556884 A JP2004556884 A JP 2004556884A JP 4623719 B2 JP4623719 B2 JP 4623719B2
- Authority
- JP
- Japan
- Prior art keywords
- plasmid dna
- naked
- growth factor
- gene
- pbs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract description 53
- 230000033115 angiogenesis Effects 0.000 title abstract description 21
- 230000001419 dependent effect Effects 0.000 title abstract description 19
- 208000024891 symptom Diseases 0.000 title abstract description 19
- 239000013612 plasmid Substances 0.000 claims abstract description 112
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000001301 oxygen Substances 0.000 claims abstract description 13
- 239000002953 phosphate buffered saline Substances 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 44
- 239000003102 growth factor Substances 0.000 claims description 38
- 238000002560 therapeutic procedure Methods 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 11
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 11
- 238000007918 intramuscular administration Methods 0.000 claims description 10
- 210000003141 lower extremity Anatomy 0.000 claims description 9
- 201000002818 limb ischemia Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 abstract description 64
- 230000001965 increasing effect Effects 0.000 abstract description 23
- 239000007927 intramuscular injection Substances 0.000 abstract description 18
- 238000010255 intramuscular injection Methods 0.000 abstract description 18
- 210000003205 muscle Anatomy 0.000 abstract description 14
- 208000027866 inflammatory disease Diseases 0.000 abstract description 5
- 206010052428 Wound Diseases 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 206010008118 cerebral infarction Diseases 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract description 3
- 208000031481 Pathologic Constriction Diseases 0.000 abstract description 2
- 206010034576 Peripheral ischaemia Diseases 0.000 abstract description 2
- 230000036262 stenosis Effects 0.000 abstract description 2
- 208000037804 stenosis Diseases 0.000 abstract description 2
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 110
- 108090000623 proteins and genes Proteins 0.000 description 69
- 108060001084 Luciferase Proteins 0.000 description 53
- 239000005089 Luciferase Substances 0.000 description 49
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 49
- 230000002491 angiogenic effect Effects 0.000 description 42
- 230000000694 effects Effects 0.000 description 33
- 238000002347 injection Methods 0.000 description 33
- 239000007924 injection Substances 0.000 description 33
- 241000700159 Rattus Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 16
- 150000001413 amino acids Chemical group 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 210000002027 skeletal muscle Anatomy 0.000 description 13
- 238000001415 gene therapy Methods 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 10
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 10
- 229940126864 fibroblast growth factor Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 108010008908 FS 069 Proteins 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000005198 spinal stenosis Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OWVNHBRJANEEKY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;hydrochloride Chemical compound Cl.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OWVNHBRJANEEKY-UHFFFAOYSA-N 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 101001124310 Bos taurus Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 238000010159 Duncan test Methods 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 101150031329 Ets1 gene Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000055702 human NOS3 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
Description
本発明は、例えば筋肉内の圧力増大または高圧酸素などの特定の条件下で、裸プラスミドDNAの筋肉内注射剤を投与することにより、血管形成依存性症状を治療および/または予防する方法に関する。
分子生物学の近年の進展により、心血管疾患に対する新規な治療戦略として、遺伝子療法が開発された。標的となる疾患は、単一遺伝子欠損疾患から、末梢動脈疾患のような、成人性のより複雑な疾患に及ぶ。例えば、重症下肢虚血は、1年間に、100万人あたり500例〜1000例が発症していると推定される(“Second European Consensus Document on Chronic Critical Leg Ischemia.”、Circulation 84(別冊4): IV 1-26(1991))。重症下肢虚血の患者においては、罹患率、死亡率および機能的関係に関連するにもかかわらず、不能症状(disabling sympton)に対する解決策として、切断が推奨されることが多い(M.R. Tyrrellら、Br. J. Surg. 80: 177-180(1993); M. Enerothら、Int. Orthop. 16: 383-387(1992))。重症下肢虚血に対する最適な医学的療法は存在しない(Circulation 84(別冊4):IV 1-26(1991))。
裸プラスミドDNAの筋肉内注射を介した、血管形成増殖因子のトランスフェクションによる血管形成の刺激の臨床試験は成功したが、トランスフェクション効率および安全性の低さを含む、ヒト遺伝子療法における問題が依然として未解決である。この観点から、裸プラスミドDNAのより高いトランスフェクション効率を達成する方法が、当技術分野において望ましい。
(1)筋肉内の圧力が増大する条件下で、適切な裸プラスミドDNAを筋肉内に注射する段階を含む、血管形成依存性症状を治療または予防する方法;
(2)注射量を多くすることにより、筋肉内の圧力が増大する、(1)の方法;
(3)プラスミドDNA投与後にPBSを注射することにより、筋肉内の圧力が増大する、(1)の方法;
(4)裸プラスミドDNAが、生理食塩水、PBS、ショ糖溶液、またはグルコース溶液で希釈される、(1)の方法;
(5)裸プラスミドDNAが血管形成増殖因子をコードする、(1)の方法;
(6)血管形成増殖因子が、肝細胞増殖因子(HGF);血管内皮増殖因子(VEGF);線維芽細胞増殖因子(FGF);ならびに、マクロファージ由来一酸化窒素合成酵素、誘導性一酸化窒素合成酵素、および脳由来一酸化窒素合成酵素を含む、一酸化窒素合成酵素からなる群より選択される、(5)の方法;
(7)血管形成依存性症状が、褥瘡および皮膚潰瘍を含む創傷;炎症性疾患;重症下肢虚血;心筋梗塞、狭心症、および心不全などの虚血性心疾患;脳梗塞;糖尿病性神経障害;ならびに脊柱管狭窄症からなる群より選択される、(1)の方法;
(8)高圧酸素(HBO)療法と組み合わせた、裸プラスミドDNAの筋肉内注射により、血管形成依存性症状を治療または予防する方法;
(9)HBO療法が、100%酸素の曝露により実施される、(8)の方法;
(10)治療対象の被験者を、プラスミドDNA投与直後にHBO療法に供する、(8)の方法;
(11)裸プラスミドDNAが、生理食塩水、PBS、ショ糖溶液、またはグルコース溶液で希釈されている、(8)の方法;
(12)裸プラスミドDNAが血管形成増殖因子をコードする、(8)の方法;
(13)血管形成増殖因子が、肝細胞増殖因子(HGF);血管内皮増殖因子(VEGF);線維芽細胞増殖因子(FGF);ならびに、マクロファージ由来一酸化窒素合成酵素、誘導性一酸化窒素合成酵素、および脳由来一酸化窒素合成酵素を含む、一酸化窒素合成酵素からなる群より選択される、(12)の方法;ならびに
(14)血管形成依存性症状が、褥瘡および皮膚潰瘍を含む創傷;炎症性疾患;重症下肢虚血;心筋梗塞、狭心症、および心不全などの虚血性心疾患;脳梗塞;糖尿病性神経障害;ならびに脊柱管狭窄症からなる群より選択される、(8)の方法。
本明細書で使用される「ある」、「一つの」、および「その」という用語は、特記しない限り、「少なくとも1つの」を意味する。
(1)直接的な筋肉内注射アプローチを使用したインビボ遺伝子導入
Sprague-Dawleyラット(400g〜500g:Charles River Breeding Laboratories)を、ペントバルビタールナトリウム(0.1ml/100mg)の腹腔内注射で麻酔した。裸ルシフェラーゼ遺伝子(500μl/動物)または対照(500μg/動物)ベクターを、27G(テルモ、厚木、日本)の針を用いて、ラットの右後肢の頸骨前筋肉の中心に直接、注意深く注射した(Y. Taniyamaら、Gene Ther. 8: 181-189(2000); M. Aokiら、Gene Ther. 7: 417-427(2000); Y. Taniyamaら、Circulation 104: 2344-2350(2001); R. Morishitaら、Circulation 105: 1491-1496(2002))。SV40プロモーターにより駆動されるルシフェラーゼ遺伝子発現ベクター(Promega Corporation、Madison、WI)を、裸ルシフェラーゼ遺伝子ベクターとして使用した。
1)筋肉内の圧力を高めるために、トランスフェクション直後に、裸ルシフェラーゼプラスミドDNAを注射した筋肉に、血圧計のマンシェットを巻いた。
2)注射部位に圧力を加えるために、プラスミドDNAを含まないPBS溶液の追加筋肉内注射を、トランスフェクションの0.5時間後または5時間後に、裸ルシフェラーゼプラスミドDNAを注射した筋肉に投与した。
ルシフェラーゼアッセイシステム(PicaGene(商標);東洋インキ、東京、日本)を使用して、ホタルルシフェラーゼ活性を測定した。裸プラスミドを後肢に直接注射することによりルシフェラーゼ遺伝子をトランスフェクションした2日後に、ラットを屠殺した。組織試料(注射部位の周囲、200 mg)を液体窒素中で急速に凍結し、溶解緩衝液中でホモジナイズした。組織溶解物を、短時間遠心分離して(3000 rpm、10分間)、上清20μlを、ルシフェラーゼアッセイ試薬100μlと混合した。発光反応の測定は、試料添加の5秒後に開始した。計測を10秒間続け、10秒目の計数を、ルシフェラーゼ活性の指数として使用した(M. Aokiら、J. Mol. Cell. Cardiol. 29: 949-959(1997))。
ラットを、ケタミン(100 mg/kg)およびキシラジン(5 mg/kg)で麻酔した。プラスミドDNAの筋肉内注射を、上記のように実施した。曝露した朝に、動物を高圧チャンバーに入れた。チャンバーに100% O2を1.5分間流し、O2レベルを>99%まで上昇させた。動物を、トランスフェクション直後、2気圧の100% O2に1時間曝露させた。
すべての値を、平均±SEMとして表現した。分散分析およびその後のDuncan試験を含むを使用して、複数回の比較における有意差を決定した。P値が0.05未満の差異を有意と考えた。
最初に、ルシフェラーゼ遺伝子を含む裸プラスミドDNAのトランスフェクション効率に対する、注射量の効果を調べた。期待したように、ルシフェラーゼ活性は、用量依存的なプラスミドDNAにより増大した(図1;p<0.01)。興味深いことに、図1に示したように、裸プラスミドDNAのトランスフェクションは、溶液(PBS)の注射量の増加に関連して増大した(p<0.01)。別々に注射する(4部位に25mlまたは8部位に12.5ml)よりも、注射量の増加(1部位に100μl)により、高いトランスフェクション効率が得られた(図2、p<0.01)。したがって、裸プラスミドDNAのトランスフェクション効率は、浸透圧に関連すると考えられた。
本発明は、従来の方法と比べてより安全かつトランスフェクション効率のより高い、プラスミドDNAに基づく遺伝子を骨格筋に送達するための変法を提供する。具体的には、本発明は、筋肉内の圧力が増大する条件下で、適切な裸プラスミドDNAを筋肉内注射することにより、疾患を治療または予防する方法を提供する。さらに、本発明の方法は、高圧酸素(HBO)療法と組み合わせて、適切な裸プラスミドDNAを筋肉内注射することにより、疾患を治療または予防する方法を提供する。
Claims (2)
- その投与直後に治療対象の被験者を高圧酸素(HBO)療法に供することをと特徴とする、筋肉内投与するための、肝細胞増殖因子(HGF)、血管内皮増殖因子(VEGF)、または線維芽細胞増殖因子(FGF)をコードする裸プラスミドDNAを有効成分として含有する、重症下肢虚血、または、心筋梗塞、狭心症、および心不全を含む虚血性心疾患の治療または予防剤。
- 裸プラスミドDNAが、生理食塩水、PBS、ショ糖溶液、またはグルコース溶液で希釈されている、請求項1記載の治療または予防剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43047802P | 2002-12-02 | 2002-12-02 | |
PCT/JP2003/015400 WO2004050126A2 (en) | 2002-12-02 | 2003-12-02 | Compositions for treating or preventing angiogenesis-dependent symptoms |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006511515A JP2006511515A (ja) | 2006-04-06 |
JP4623719B2 true JP4623719B2 (ja) | 2011-02-02 |
Family
ID=32469479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004556884A Expired - Lifetime JP4623719B2 (ja) | 2002-12-02 | 2003-12-02 | 血管形成依存性症状を治療または予防する方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7259149B2 (ja) |
EP (1) | EP1567197B1 (ja) |
JP (1) | JP4623719B2 (ja) |
CN (1) | CN1717254A (ja) |
AT (1) | ATE474604T1 (ja) |
AU (1) | AU2003302590B2 (ja) |
CA (1) | CA2507534A1 (ja) |
DE (1) | DE60333476D1 (ja) |
WO (1) | WO2004050126A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1182874C (zh) * | 1999-10-29 | 2005-01-05 | 安增子摩祺株式会社 | 糖尿病性局部缺血疾病的基因治疗制剂 |
WO2006046766A1 (ja) * | 2004-10-29 | 2006-05-04 | Anges Mg, Inc. | 心不全治療のための遺伝子治療 |
US20090214496A1 (en) * | 2006-01-30 | 2009-08-27 | Licentia Ltd. | Bmx/etk tyrosine kinase gene therapy materials and methods |
RU2542385C2 (ru) | 2012-08-31 | 2015-02-20 | Общество с ограниченной ответственностью "НекстГен" | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
RU2612497C2 (ru) | 2015-05-26 | 2017-03-09 | Общество с ограниченной ответственностью "НекстГен" | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5941431U (ja) * | 1982-09-07 | 1984-03-16 | 斎藤 春雄 | 治療用高圧タンクにおける緊急脱出扉装置 |
JPS6183121A (ja) * | 1984-10-01 | 1986-04-26 | Green Cross Corp:The | 虚血性潰瘍治療剤 |
US20020137707A1 (en) * | 1997-12-30 | 2002-09-26 | Monahan Sean D. | Intravascular delivery of non-viral nucleic acid |
DE69736981D1 (de) | 1996-05-01 | 2007-01-04 | Imarx Pharmaceutical Corp | In vitro verfahren zum einbringen von nukleinsäuren in eine zelle |
US6312663B1 (en) * | 1999-03-19 | 2001-11-06 | Joseph V. Boykin, Jr. | Prediction of diabetes impaired wound healing by urinary nitrate assay |
NZ514305A (en) * | 1999-04-16 | 2004-01-30 | Univ Yale | eNOS mutations useful for gene therapy and therapeutic screening |
JP2001017188A (ja) * | 1999-04-22 | 2001-01-23 | Kyowa Hakko Kogyo Co Ltd | 新規なvegf/pdgf様因子 |
DE60134021D1 (de) * | 2000-06-27 | 2008-06-26 | Anges Mg Inc | Pharmazeutische zubereitungen zur angiogenese-therapie |
EP2314434A3 (en) * | 2002-07-18 | 2013-08-21 | Mitsubishi Rayon Co., Ltd. | Intermediate material for FRP molding and fabrication process therefor |
JP4420633B2 (ja) * | 2002-08-08 | 2010-02-24 | アンジェスMg株式会社 | 血管新生治療剤 |
US7591973B2 (en) * | 2002-11-28 | 2009-09-22 | Mitsubishi Rayon Co., Ltd. | Method for producing a fiber-reinforced composite material plate |
-
2003
- 2003-12-02 AT AT03812366T patent/ATE474604T1/de not_active IP Right Cessation
- 2003-12-02 CA CA002507534A patent/CA2507534A1/en not_active Abandoned
- 2003-12-02 WO PCT/JP2003/015400 patent/WO2004050126A2/en active Application Filing
- 2003-12-02 DE DE60333476T patent/DE60333476D1/de not_active Expired - Lifetime
- 2003-12-02 US US10/536,274 patent/US7259149B2/en not_active Expired - Lifetime
- 2003-12-02 AU AU2003302590A patent/AU2003302590B2/en not_active Ceased
- 2003-12-02 JP JP2004556884A patent/JP4623719B2/ja not_active Expired - Lifetime
- 2003-12-02 CN CNA2003801045974A patent/CN1717254A/zh active Pending
- 2003-12-02 EP EP03812366A patent/EP1567197B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1567197A2 (en) | 2005-08-31 |
EP1567197B1 (en) | 2010-07-21 |
DE60333476D1 (de) | 2010-09-02 |
WO2004050126A2 (en) | 2004-06-17 |
CN1717254A (zh) | 2006-01-04 |
AU2003302590A1 (en) | 2004-06-23 |
AU2003302590B2 (en) | 2008-11-06 |
ATE474604T1 (de) | 2010-08-15 |
JP2006511515A (ja) | 2006-04-06 |
US7259149B2 (en) | 2007-08-21 |
CA2507534A1 (en) | 2004-06-17 |
US20060135452A1 (en) | 2006-06-22 |
WO2004050126A3 (en) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU767662B2 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF | |
US6583276B1 (en) | Angiogenic factors and use thereof in treating cardiovascular disease | |
US20020172663A1 (en) | Localized myocardial injection method for treating ischemic myocardium | |
CA2188575A1 (en) | Gene transfer-mediated angiogenesis therapy | |
JP3865632B2 (ja) | 心筋症遺伝子治療 | |
JP4623719B2 (ja) | 血管形成依存性症状を治療または予防する方法 | |
JP3877148B2 (ja) | 糖尿病性虚血性疾患遺伝子治療 | |
US8445454B2 (en) | Use on minicircle vectors for cardiac gene therapy | |
US7074399B2 (en) | Treatment of inflammation with p20 | |
CN107073078B (zh) | 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物 | |
US20030165467A1 (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
JP2001072607A (ja) | 新規血管内皮機能改善法 | |
WO2003062373A2 (en) | Methods and materials for the recruitment of endothelial cells | |
Hammond | Intracoronary gene transfer of fibroblast growth factor in experimental and clinical myocardial ischemia | |
EP1426444A2 (en) | Use of the angiogenic factor VEGF145 in treating cardiovascular diseases | |
RU2021105703A (ru) | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение | |
AU2004200697A1 (en) | Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF | |
WO2001023003A1 (en) | Tissue flap angiogenesis | |
IL155940A (en) | Promoters unique to endothelial cells and methods of using them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101028 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101101 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4623719 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131112 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |